Prof. Dr. med. Matthias Schwab

Full Professor at Department of Clinical Pharmacology, University of Tübingen

Head of the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert Bosch Hospital Stuttgart

Auerbachst. 112

D-70193 Stuttgart, Germany

Phone: +49-711-8101-3700

Email: Matthias.schwab[at]



Wikipedia Seite

Clinical Pharmacology at UKT

Pharamacogenomics and Cancer


Download CV


10 most relevant publications



Variation in drug disposition and response among patients is a major concern associated with many pharmaceuticals used in all disciplines of medicine. The clinical relevance of variability is most evident with drugs that have a narrow therapeutic window (i.e., the dose used is close to the dose probably resulting in drug-related toxicity in most individuals). With increasingly comprehensive information available from the Human Genome Project Pharmacogenomics aims to identify underlying factors which have profound effects on patient outcome as well as drug toxicity. We are particularly interested in the identification and elucidation of genetic variants relevant for ADME processes such as drug metabolizing enzymes, drug transporters and nuclear receptors. However, it is unlikely that one single gene will affect exclusively disease and/or treatment outcome, and therefore a more comprehensive approach is required to consider genetics in entire biological/ pharmacological pathways. Recently developed ‘-omics appoaches’ (e.g., genomics, transcriptomics, proteomics, metabolomics) will be helpful to identify further putative targets for better prediction of drug response and will complement each other. Microarray technologies (e.g. cDNA arrays, GWA) have shown to be helpful for identifying novel susceptibility genes, redefining disease diagnosis and predicting therapy response to specific drugs. Additional information on the epigenetic level (e.g. methylation, miRNA) needs consideration.


Research Interests


  • Pharmacogenomics / Epigenetics of drug metabolizing enzymes, drug transporters and nuclear receptors  
  • Pharmacogenomics of anticancer and immunosuppressive drugs
  • Drug-Drug Interaction and cliniical consequences
  • Pediatric clinical pharmacology
  • Novel methodologies in genomic research and molecular diagnostics
  • Novel therapeutic strategies in renal cancer

Joint Research Projects


Deutsche Krebshilfe, 70112564: Duale ErbB-Rezeptor Blockade – Ein neuer therapeutischer Ansatz zur Behandlung des Kolorektalkarzinoms.


DKTK (DKFZ, Germany): Novel Risk adapted prevention strategies for people with a family history of cancer.


BMBF Jülich, Germany, 031A575A: Replacement of Experimental Surgical Transplantations In the central Nervous system (RESTRAIN)


BMBF, Germany, 031L0037: Liver Systems Medicine: "Early Metabolic Injury (LiSyM) a systems approach to disease initiation in Nash". WPC.2.


BMBF, Germany, 01EK1509A: Innovationen für die Individualisierte Medizin: Genotype and phenotype guided supplementation of TAMoxifen standard therapy with ENDOXifen in breast cancer patients (TAMENDOX).


EU Horizon 2020-PHC-24-2015, 668353: U-PGx Ubiquitous Pharmacogenomics: Making actionable pharmacogenomics data and effective treatment optimization accessible to every European citizen.